{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:47:43Z","timestamp":1790200063532,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","award":["R501-LR-RND002-0000000996-0000"],"award-info":[{"award-number":["R501-LR-RND002-0000000996-0000"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015515","name":"Kementerian Pendidikan Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003093","name":"Kementerian Pendidikan Malaysia - Pendidikan Tinggi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jiph.2025.102871","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:17:46Z","timestamp":1749208666000},"page":"102871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Addressing antimicrobial resistance: Structural insights into cefiderocol\u2019s mode of action and emerging resistance mechanisms"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-9381","authenticated-orcid":false,"given":"Mohd Zulkifli","family":"Salleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jiph.2025.102871_bib1","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s44259-023-00013-4","article-title":"Di-berberine conjugates as chemical probes of Pseudomonas aeruginosa MexXY-OprM efflux function and inhibition","volume":"1","author":"Kavanaugh","year":"2023","journal-title":"npj Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib3","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1038\/s41467-020-18770-5","article-title":"Antibiotic export by MexB multidrug efflux transporter is allosterically controlled by a MexA-OprM chaperone-like complex","volume":"11","author":"Glavier","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jiph.2025.102871_bib4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiph.2025.102871_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy","volume":"68","author":"Teran","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2025.102871_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41429-024-00762-y","article-title":"In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol","author":"Kriz","year":"2024","journal-title":"J Antibiot"},{"issue":"7","key":"10.1016\/j.jiph.2025.102871_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40560-020-0429-6","article-title":"Molecular diversity of extended-spectrum \u03b2-lactamases and carbapenemases, and antimicrobial resistance","volume":"8","author":"Sawa","year":"2020","journal-title":"J Intensive Care"},{"issue":"Suppl. 7","key":"10.1016\/j.jiph.2025.102871_bib11","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jiph.2025.102871_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37201\/req\/s02.02.2022","article-title":"Mechanism of action of cefiderocol","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev. Esp. Quimioter. Publ. Soc. Esp. Quimioter."},{"issue":"4","key":"10.1016\/j.jiph.2025.102871_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02531-16","article-title":"Structure and function of the PiuA and PirA siderophore-drug receptors from Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"61","author":"Moyni\u00e9","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiph.2025.102871_bib14","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2025.102871_bib15","doi-asserted-by":"crossref","DOI":"10.1039\/D4SC04937C","article-title":"Structural basis of Pseudomonas aeruginosa penicillin binding protein 3 inhibition by the siderophore-antibiotic cefiderocol","author":"Smith","year":"2024","journal-title":"Chem Sci"},{"issue":"51","key":"10.1016\/j.jiph.2025.102871_bib16","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1073\/pnas.1013092107","article-title":"Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa","volume":"107","author":"Han","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.jiph.2025.102871_bib17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 7","key":"10.1016\/j.jiph.2025.102871_bib18","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2025.102871_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jiph.2025.102871_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","article-title":"Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants","volume":"41","author":"Poirel","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"issue":"6","key":"10.1016\/j.jiph.2025.102871_bib21","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2025.102871_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.741940","article-title":"Cefiderocol: an overview of its in-vitro and in-vivo activity and underlying resistant mechanisms","volume":"8","author":"Yao","year":"2021","journal-title":"Front Med"},{"issue":"30","key":"10.1016\/j.jiph.2025.102871_bib23","doi-asserted-by":"crossref","first-page":"21328","DOI":"10.1039\/D4RA04302B","article-title":"Cefiderocol susceptibility endows hope in treating carbapenem-resistant Pseudomonas aeruginosa: insights from in vitro and in silico evidence","volume":"14","author":"Basu","year":"2024","journal-title":"RSC Adv"},{"issue":"11","key":"10.1016\/j.jiph.2025.102871_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in Acinetobacter baumannii: roles of \u03b2-lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2025.102871_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","article-title":"The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis","volume":"32","author":"Sauvage","year":"2008","journal-title":"FEMS Microbiol Rev"},{"issue":"7","key":"10.1016\/j.jiph.2025.102871_bib26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/jac\/dkad172","article-title":"In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa","volume":"78","author":"Gomis-Font","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jiph.2025.102871_bib27","doi-asserted-by":"crossref","first-page":"dlad107","DOI":"10.1093\/jacamr\/dlad107","article-title":"In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitors","volume":"5","author":"Shields","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"12","key":"10.1016\/j.jiph.2025.102871_bib28","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1128\/AAC.00459-11","article-title":"Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii","volume":"55","author":"Cay\u00f4","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiph.2025.102871_bib29","doi-asserted-by":"crossref","first-page":"dlaa081","DOI":"10.1093\/jacamr\/dlaa081","article-title":"Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study","volume":"2","author":"Sato","year":"2020","journal-title":"JAC Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.jiph.2025.102871_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02670-21","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.jiph.2025.102871_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00084-22","article-title":"Emergence of high-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China","volume":"10","author":"Lan","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"9","key":"10.1016\/j.jiph.2025.102871_bib32","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3201\/eid2909.230390","article-title":"Population analysis of Escherichia coli sequence type 361 and reduced cefiderocol susceptibility, France","volume":"29","author":"Jousset","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.jiph.2025.102871_bib33","doi-asserted-by":"crossref","first-page":"1172.e7","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime\u2013avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","article-title":"In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects","volume":"41","author":"Bianco","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with an increase in blaNDM-5 copy number and gene expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"10.1016\/j.jiph.2025.102871_bib36","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jiph.2025.102871_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa439.1636","article-title":"1455. Potential mechanisms of cefiderocol MIC increase in enterobacterales in in vitro resistance acquisition studies","author":"Yamano","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.jiph.2025.102871_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00828-22","article-title":"Structural basis of PER-1-mediated cefiderocol resistance and synergistic inhibition of PER-1 by cefiderocol in combination with avibactam or durlobactam in Acinetobacter baumannii","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2025.102871_bib39","article-title":"Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jiph.2025.102871_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.jiph.2025.102871_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3201\/eid3101.241426","article-title":"Cefiderocol resistance conferred by plasmid-located ferric citrate transport system in KPC-producing Klebsiella pneumoniae","volume":"31","author":"Polani","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2025.102871_bib42","first-page":"e01548","article-title":"Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectru","volume":"68","author":"Christophe","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2025.102871_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2021.09.016","article-title":"International circulation of aztreonam\/avibactam-resistant NDM-5-producing Escherichia coli isolates: successful epidemic clones","author":"Sadek","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"10.1016\/j.jiph.2025.102871_bib44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jiph.2024.02.006","article-title":"Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it\u2019s even arrived?","volume":"17","author":"Russo","year":"2024","journal-title":"J Infect Public Health"},{"issue":"2","key":"10.1016\/j.jiph.2025.102871_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02011-21","article-title":"New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae","volume":"66","author":"Nurjadi","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"31","key":"10.1016\/j.jiph.2025.102871_bib46","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.1021\/bi0109358","article-title":"Structures of ceftazidime and its transition-state analogue in complex with AmpC \u03b2-lactamase: implications for resistance mutations and inhibitor design","volume":"40","author":"Powers","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.jiph.2025.102871_bib47","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.18986","article-title":"Current trends in the epidemiology of multidrug-resistant and beta-lactamase-producing Pseudomonas aeruginosa in Asia and Africa: a systematic review and meta-analysis","volume":"13","author":"Salleh","year":"2025","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.jiph.2025.102871_bib48","doi-asserted-by":"crossref","first-page":"538.e7","DOI":"10.1016\/j.cmi.2022.11.014","article-title":"Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"29","author":"L\u00f3pez-Causap\u00e9","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jiph.2025.102871_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01779-21","article-title":"In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniae due to functional loss of CirA","volume":"9","author":"McElheny","year":"2021","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:15:55Z","timestamp":1778829355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125002205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1876034125002205"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102871","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing antimicrobial resistance: Structural insights into cefiderocol\u2019s mode of action and emerging resistance mechanisms","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102871"}}